Months re­moved from a $118M Se­ries B, Min­eralys push­es ahead with PhII hy­per­ten­sion da­ta

In June, the Philadel­phia-based biotech Min­eralys com­plet­ed a $118 mil­lion Se­ries B fi­nanc­ing with back­ing from names like RA Cap­i­tal, push­ing to­ward fin­ish­ing a Phase II tri­al for its hy­per­ten­sion drug, cur­rent­ly named MLS-101. Now the com­pa­ny has lift­ed the cur­tain on the topline Phase II re­sults for sev­er­al dos­es of the can­di­date.

The Phase II study for MLS-101, Min­eralys’ al­dos­terone syn­thase in­hibitor for treat­ing hy­per­ten­sion and its as­so­ci­at­ed car­dio­vas­cu­lar dis­eases, has reached its pri­ma­ry end­point, show­ing a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful” re­duc­tion in sys­tolic blood pres­sure (SBP) for pa­tients with in­ad­e­quate­ly con­trolled hy­per­ten­sion, and who are on at least two back­ground meds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER